Accelerate Diagnostics Inc. (AXDX) Given Average Recommendation of “Strong Buy” by Brokerages
Accelerate Diagnostics Inc. (NASDAQ:AXDX) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus target price of $25.00 for the company and are predicting that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also given Accelerate Diagnostics an industry rank of 105 out of 265 based on the ratings given to its competitors.
Several analysts recently issued reports on AXDX shares. BTIG Research upgraded Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a report on Thursday, August 25th. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, October 10th. Finally, JPMorgan Chase & Co. increased their price objective on Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Tuesday, August 9th.
Accelerate Diagnostics (NASDAQ:AXDX) traded up 1.83% on Tuesday, hitting $25.10. The company had a trading volume of 112,014 shares. The firm’s 50 day moving average price is $25.73 and its 200 day moving average price is $18.46. Accelerate Diagnostics has a 12-month low of $10.29 and a 12-month high of $28.50. The stock’s market cap is $1.29 billion.
A number of institutional investors have recently bought and sold shares of the company. Independence Advisors LLC acquired a new position in Accelerate Diagnostics during the third quarter valued at approximately $354,000. Stifel Financial Corp acquired a new position in Accelerate Diagnostics during the second quarter valued at approximately $487,000. Barclays PLC increased its position in Accelerate Diagnostics by 137,400.0% in the second quarter. Barclays PLC now owns 86,625 shares of the company’s stock valued at $1,247,000 after buying an additional 86,562 shares during the last quarter. KCG Holdings Inc. increased its position in Accelerate Diagnostics by 123.9% in the second quarter. KCG Holdings Inc. now owns 24,114 shares of the company’s stock valued at $347,000 after buying an additional 13,342 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its position in Accelerate Diagnostics by 14.5% in the second quarter. Nuveen Asset Management LLC now owns 710,571 shares of the company’s stock valued at $10,225,000 after buying an additional 90,030 shares during the last quarter. 35.66% of the stock is currently owned by hedge funds and other institutional investors.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.